Trends in anti-neuropathic medications turnover in Iraq

Abstract

Abstract Objectives Neuropathic pain (NP) is a type of chronic pain. Numerous diseases and/or lesions are associated with the development of NP, and diabetes mellitus is the most prevalent cause. Several classes of medications were recommended and/or approved as anti-neuropathic medications. This study aimed to examine the trends in the turnover of anti-neuropathic medications in Iraq. Methods This was a retrospective analysis of the turnover of selected anti-neuropathic medications in the Iraqi market derived from Advanced Marketing Statistics between 2017 and 2021. The sales units were converted to defined daily doses. Regression analysis and correlation analysis were used to compare the turnover of the medications. Key findings The overall volume of turnover of anti-neuropathic medications increased between 2017 and 2021. The anti-neuropathic market domination was shifted from carbamazepine to pregabalin, in which the average increase in pregabalin turnover of 60% [95% CI (confidence interval) 37.6–82.5] quarterly to achieve 42% of the market share (highest sales) by 2021. The overall expenditure on anti-neuropathic medications increased steadily over the study period. Conclusions The market of anti-neuropathic medications’ domination was shifted from the older antiepileptic drug (AED) (carbamazepine) to the newer AED (pregabalin). The availability and affordability of less expensive generic versions of these agents, together with the better safety profiles of the newer agents were the main driver for this shift. This indeed allowed Iraqi physicians to adhere to the latest international guidelines.